U.S. Markets open in 3 hrs 3 mins

Amarin Is Poised for Solid Revenue Growth in Fiscal 2018

Margaret Patrick
Amarin Is Poised for Solid Revenue Growth in Fiscal 2018

Amarin witnessed a 17% YoY rise in Vascepa product revenues in the second quarter due to a solid rise in prescriptions for the drug and improved productivity across the company. According to the company’s second-quarter conference call, Symphony Health Solutions and IQVIA estimated the rise in normalized Vascepa prescriptions the second quarter of 77,000 and 84,000, respectively, on a YoY basis.